Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Neurol Sci
Autori principali: Tazza, F., Lapucci, C., Cellerino, M., Boffa, G., Novi, G., Poire, I., Mancuso, E., Bruschi, N., Sbragia, E., Laroni, A., Capello, E., Inglese, M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier B.V. 2021
Soggetti:
Clinical Short Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8133824/
https://ncbi.nlm.nih.gov/pubmed/34044238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jns.2021.117501
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi